Antibody recognizing folate receptors alpha and beta
US-2015343088-A1 · Dec 3, 2015 · US
US9962423B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9962423-B2 |
| Application number | US-201414774764-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 11, 2014 |
| Priority date | Mar 13, 2013 |
| Publication date | May 8, 2018 |
| Grant date | May 8, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds. Typically the recombinant protein has a polypeptide of viral, fungal, or bacterial origin such as secreted effector proteins AvrA and YopJ. In certain embodiments, the disclosure relates to treating or preventing autoimmune diseases, cancer, or inflammatory diseases, or conditions such as inflammatory bowel disease (IBD).
Opening claim text (preview).
The invention claimed is: 1. Particles comprising a) recombinant AvrA proteins; and b) linking groups comprising disulfide bonds, wherein the linking groups conjugate the recombinant AvrA proteins to form the particles and wherein the size of the particles are between 50 nm and 200 nm in diameter. 2. The particles of claim 1 , wherein the recombinant AvrA is mAvrA(C186A). 3. The particles of claim 1 , wherein the recombinant AvrA proteins are fusion proteins comprising bovine serum albumin (BSA), green fluorescent protein (GFP), glutathione S-transferase (GST), polyhistidine, polylysine, or combinations thereof. 4. The particles of claim 1 , wherein the linking groups have the following formula, wherein, n is 1 to 100, L forms amides to the recombinant AvrA proteins, and X is at each occurrence individually and independently selected from O, NH, C═O, CH 2 , OCH 2 , CH 2 O, NHCH 2 , CH 2 NH, OCH 2 CH 2 , CH 2 CH 2 O, NHCH 2 CH 2 , or CH 2 CH 2 NH. 5. The particles of claim 4 , wherein X is (CH 2 )n wherein n is 1 to 4. 6. A pharmaceutical composition comprising the particles of claim 1 and a pharmaceutically acceptable excipient.
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title
the form being a nanoparticle, e.g. an immuno-nanoparticle · CPC title
containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP] · CPC title
Salmonella (G) · CPC title
containing a His-tag · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.